{
    "contents" : "library(survival)\nlibrary(foreign)\n\nrm(list=ls(all=TRUE))\n################################\n# CHAPTER 9 Practice\n################################\n\n# Answer questions 1 to 15 as true or false.\n\n################################\n# Question 1\n################################\n\n# A competing risk is an event-type (i.e., failure status) that can occur simultaneously with another \n# event of interest on the same subject.\n\n# False\n\n# Page 430:\n# Competing risks occur when there are at least two possible ways that a person can fail, but only one\n# failure type can actually occur.\n\n################################\n# Question 2\n################################\n\n# An example of competing risks survival data is a study in which patients receiving radiotherapy for head and \n# neck cancer may either die from their cancer or from some other cause of death.\n\n# True\n\n################################\n# Question 3 \n################################\n\n# If all competing risks in a given study are different causes of death, then it is possible to have both competing \n# risks and recurrent events in the same study.\n\n# False\n\n# Page 430:\n\n# Death is a one time event and cannot be recurrent.\n\n################################\n# Question 4\n################################\n\n# Suppose patients with advanced-stage cancer may die after surgery before their hospital stay is long enough to \n# get a hospital infection. Then such deaths from surgery reduce the hospital’s burden of infection control.\n\n# True\n\n################################\n# Question 5\n################################\n\n# The typical approach for analyzing competing risks using a Cox PH model involves fitting separate models for \n# each competing risk ignoring the other competing risks.\n\n# False\n\n# Page 434:\n\n# The typical approach for analyzing competing risks data uses the Cox (PH) model to separately estimate hazards and \n# corresponding hazard ratios for each failure type, treating the other (competing) failure types as censored in addition \n# to those who are censored from loss to follow-up or withdrawal.\n\n# Referred to as Method 1\n\n################################\n# Question 6\n################################\n\n# Suppose that a cause-specific risk of interest is development of lung metastasis, and a competing risk is local recurrence \n# of a lung tumor. Then a patient who develops a local recurrence is treated as a failure in a competing risk analysis.\n\n# False\n\n# Page 434:\n\n# The patient would be treated as censored.\n\n################################\n# Question 7\n################################\n\n# When there are no competing risks, then any study subject in the risk set at a given time has the same risk for failing \n# as any other subject in the risk set with the same values for covariate predictors at time t.\n\n# False/True?\n\n# Page 438\n\n# According to answer key, it is false.  Says that it would be true if the censoring is independent.\n\n#????????????????????????????????\n\n################################\n# Question 8\n################################\n\n# If, when analyzing competing risks survival data, it is assumed that censoring is independent, then a subject in the \n# risk set at time t is as likely to fail from any competing risk as to be lost to follow-up.\n\n# True\n\n# Page 438\n\n################################\n# Question 9\n################################\n\n# When a sensitivity analysis indicates that a worst-case scenario gives meaningfully different results from an analysis \n# that assumes independence of competing risks, then there is evidence that the independence assumption is violated.\n\n# False\n\n# Page 441\n\n# If, on the other hand, the sensitivity analysis provides results that meaningfully differ from results obtained \n# under the independence assumption, the investigator learns only the extremes to which the results could be biased\n# without adjusting for the actual bias.\n\n################################\n# Question 10\n################################\n\n# The typical competing risk analysis assumes that competing risks are independent even if this assumption is not true.\n\n# True\n\n# Page 443\n\n# The typical survival analysis assumes that the independence assumption is satisfied when there are\n# competing risks, even if this is not the case.\n\n################################\n# Question 11\n################################\n\n# The Cumulative Incidence Curve (CIC) provides risk estimates for the occurrence of a cause-specific event in \n# the presence of competing risks.\n\n# True\n\n# Starting on Page 444\n\n# ??????????????????????  Maybe more explanation?\n\n################################\n# Question 12\n################################\n\n# CIC = 1 - KM, where KM denotes the Kaplan–Meier curve.\n\n# False\n\n# Page 447\n\n# In the simplest case, if there is only 1 case CIC = 1 - KM.\n\n################################\n# Question 13\n################################\n\n# A CIC for a cause-specific event that ignores the control of covariates does not require the assumption of independent \n# competing risks.\n\n# True\n\n# ?????????????????\n\n################################\n# Question 14\n################################\n\n# A Cumulative Probability Curve (CPC) gives the probability of experiencing an event c by time t, given that an \n# individual has experienced any of the other competing risks by time t.\n\n# False\n\n# Page 453 \n\n# Put simply, the CPCc is the probability of experiencing an event c by time t, given that an\n# individual has not experienced any of the other competing risks by time t.\n\n\n################################\n# Question 15\n################################\n\n# If CICc = .4, then CPC = .4/.6 = .667.\n\n# False\n\n# Page 454\n\n# CPCc = CICc/(1-CICc')\n\n################################\n# Question 16\n################################\n\n# The Lunn–McNeil (LM) approach fits a single stratified Cox model using an augmented dataset to obtain the same \n# results as obtained by fitting separate Cox models for each cause specific competing risk.\n\n# True\n\n# Page 455\n\n################################\n# Question 17\n################################\n\n# An advantage of the Lunn–McNeil (LM) approach over the approach that fits separate Cox models is that the LM approach \n# allows for testing whether a no-interaction SC model might be preferable to an interaction SC model.\n\n# True\n\n# ?????????????????????\n\n################################\n# Question 18\n################################\n\n#Given the LM model stratified on two cause specific events, Cancer and CVD:\n \n# h'g(t,X)= h'0g(t)exp[B1Rx + B2Age + theta1(DxRx) +theta2(DxAge)],\n# \n# g = 1, 2 where\n# D = 0 if Ca and = 1 if CVD\n# \n# then\n# \n# HRcvd(Rx = 1 vs. Rx = 0) = exp[B1 + theta1]\n\n# True\n\n# ????????????????????????????\n################################\n# Question 19\n################################\n\n#??????????????????????????????\n\n################################\n# Question 20\n################################\n\n#??????????????????????????????\n\n################################\n# Questions 21-26\n################################\n\n# Consider a hypothetical study of the effect of a bone marrow transplant for leukemia on leukemia-free survival,\n# where transplant failures can be of one of two types: relapse of leukemia and nonrelapse death (without prior\n# relapse of leukemia). Suppose that in hospital A, 100 patients undergo such a transplant and that within the\n# first 4 years post-transplant, 60 die without relapse by year 2 and 20 relapse during year 4. Suppose that in hospital\n# B, 100 patients undergo such a transplant but posttransplant, there are 20 non-relapse deaths by year 1, 15\n# relapses during year 2, 40 non-relapse deaths between years 3 and 4, and 5 relapses during year 4.\n\n\n################################\n# Question 21\n################################\n\n# What are the competing risks in this study?\n\n# The competing risks are: relapse of leukemia and nonrelapse death (without prior relapse of leukemia)\n\n################################\n# Question 22\n################################\n\n# What is the proportion of initial patients in hospitals A and B, respectively, that have leukemia relapse by 4 years?\n\n# Hospital A = 20/100\n# Hospital B = 20/100\n\n################################\n# Question 23\n################################\n\n# How have both tables treated the competing risk for nonrelapse death in the calculation of the KM probabilities?\n\n# Both have treated the competing risk for nonrelapse death as a censored event.\n\n################################\n# Question 24\n################################\n\n# Why are the KM probabilities different at 4 years for each hospital?\n\n# The KM probabilities are different at year 4 because even though they had the same proportion of leukemia relapses,\n# the competing risks caused different censorship patterns.\n\n################################\n# Question 25\n################################\n\n# Compute the CIC curves for each hospital using the following tables.\n\n\n# Hospital A\n\n# tf  nf  mf  hca(tf) s(tf-1) Ica(tf) CIC(tf)\n\n# 0   100 0   0\n# 2   40  0   0       1       0       0\n# 4   40  20  0.5     0.4     0.2     0.2\n\n\n# Hospital B\n\n# tf  nf  mf  hca(tf) s(tf-1) Ica(tf) CIC(tf)\n\n# 0   100 0   0\n# 1   80  0   0       1       0       0\n# 2   80  15  0.1875  0.8     0.15    0.15\n# 3   65  0   0       0.65    0       0.15\n# 4   25  5   0.20    0.25    0.05    0.20\n\n################################\n# Question 26\n################################\n\n# Why are the CIC probabilities the same at 4 years?\n\n# The CIC probabilities are marginal probabilites that are not influenced by any patterns of censorship.\n\n################################\n# Questions 27-34\n################################\n\n# Consider a hypothetical study to assess the effect of a new hospital infection control strategy for patients who\n# undergo heart transplant surgery in a given hospital. The exposure variable of interest is a binary variable Group\n# (G): G = 0 for those patients receiving heart transplants from 1992 through 1995 when the previous hospital control\n# strategy was used; G = 1 for those patients receiving heart transplants from 1996 through 1999 when the new\n# hospital infection control strategy was adopted. The primary event of interest is getting a hospital infection after\n# surgery. A competing risk is death during recovery from surgery without getting a hospital infection. Control variables\n# being considered are tissue mismatch score (TMS) at transplant and AGE at transplant. The outcome variable of\n# interest is time (DAYS after surgery) until a patient developed a hospital infection.\n\n################################\n# Question 27\n################################\n\n# State a cause-specific no-interaction Cox PH model for assessing the effect of group status (G) on time\n# until a hospital infection event.\n\n# ?????????????????????????????\n\n################################\n# Question 28\n################################\n\n# When fitting the model given in Question 27, which patients should be considered censored?\n\n# Patients dying during recovery from surgery without getting a hospital infection.  Also censor patients\n# who are lost to follow-up or withdraw from the study.\n\n################################\n# Question 29\n################################\n\n# Describe or provide a table that would show how the data on the ith patient should be augmented for input\n# into a Lunn–McNeil (LM) model for this analysis\n\n\n\n\n\n\n\n\n\n\n\n\n\n",
    "created" : 1427812476842.000,
    "dirty" : false,
    "encoding" : "UTF-8",
    "folds" : "",
    "hash" : "3539016299",
    "id" : "197E9625",
    "lastKnownWriteTime" : 1428415656,
    "path" : "~/GitHub/SurvivalExercises/Thomas/Survival Analysis/Ch9_Practice_Test_Questions_Table_Replication.R",
    "project_path" : "Thomas/Survival Analysis/Ch9_Practice_Test_Questions_Table_Replication.R",
    "properties" : {
    },
    "source_on_save" : false,
    "type" : "r_source"
}